Fieve Clinical Research | New York, NY

Research site

(Unclaimed)

Location

587 5th Avenue Suite 802, New York, New York, United States of America

Site insights

Top conditions

Top treatments

Rapastinel

Aticaprant

SPD489

Cariprazine

Rimegepant

IPX159

Quetiapine XR

Zavegepant

Psilocybin

BHV-3500

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 23 total trials

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant (VENTURA-7)

The purpose of this study is to evaluate how well aticaprant works as compared with placebo when given along with an antidepressant therapy in improv...

Enrolling

Anhedonia

Depressive Disorder, Major

Drug: Aticaprant

Other: Placebo

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-1)

The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving dep...

Enrolling

Depressive Disorder, Major

Anhedonia

Drug: Aticaprant

Other: Placebo

A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)

The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepres...

Enrolling

Depressive Disorder, Major

Drug: Aticaprant

Locations recently updated

Efficacy and Safety Trial of BHV-2100 for the Acute Treatment of Migraine

This study is designed to identify at least one dose of BHV-2100 that is safe and effective in reducing headache pain and other symptoms in the treat...

Enrolling

Migraine

Drug: Placebo

Drug: BHV-2100

Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

Efficacy, Safety, and Tolerability of two administrations of COMP360 in participants with treatment-resistant depression (TRD)

Enrolling

Treatment Resistant Depression

Drug: Psilocybin

Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting

Episodic Migraine

Drug: Placebo

Drug: BOTOX